VivaZome and BIA Separations to collaborate on downstream technology for exosome purification

VivaZome Therapeutics Pty Ltd and BIA Separations – a part of the life science group Sartorius – today announced that they have entered into a collaborative research project for exosome purification. BIA’s unique CIM (Convective Interaction Media) monolith chromatography technology will be used to purify exosomes from VivaZome’s cell cultures, with the aim of developing a high-efficiency downstream purification and concentration process for exosome production.

Under the collaborative arrangement, VivaZome will provide exosome-rich, cell culture supernatant produced by VivaZome’s preferred cell type. BIA’s expert Bioprocessing Team, located in Ajdovščina, Slovenia, will use the VivaZome material to evaluate and optimise the monolith technology with the objective of demonstrating high purification capability, efficient removal of contaminants, fast flow rates and scale-ability. VivaZome and BIA will each contribute their expertise in exosome characterisation and analytics.

VivaZome’s Chief Executive Officer, Dr David Haylock, stated: “VivaZome is delighted to enter into this international collaboration. BIA brings high-level expertise and unique technology to the table. The monolith technology has been shown to work well with exosomes and we look forward to building on that experience. BIA and VivaZome recognise that the development of a high-efficiency downstream separation and concentration process is key to the manufacture of therapeutic exosomes and to realising their therapeutic potential.”

BIA’s Chief Scientific Officer, Pete Gagnon added: “Monoliths permit high flow rates that translate to short process time, and high exosome capacity that translates to low material consumption. Those features enable the high productivity needed to put exosome manufacturing on a strong economical foundation. BIA’s parallel development of exosome-customized surface chemistries and fast analytical methods meanwhile provides the additional elements needed to purify clinical-quality exosomes.”

In further news, VivaZome advises that CEO David Haylock is presenting at Biotech Showcase 2021, which will be delivered digitally on January 11-15, 2021. In its thirteenth consecutive year, the Biotech Showcase is a USA-based investor conference devoted to providing private and micro-mid-cap biotechnology companies an opportunity to present to, and meet with, biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The VivaZome presentation is available now as on-demand content on the Biotech Showcase platform and is expected to draw significant interest. Go to http://events.ebdgroup.com/bts/core/presenting-companies2021.php?speakerSearch=vivazome.

Source – Vivazome